NASDAQ: AIDX · Industrial Applications and Services · 3 alerts · CIK 1139685
Share price
$0.1850Close, Nov 16
Market cap
$1.96M
Shares outstanding
10.61MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Testing LaboratoriesSIC 8734
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All 20/20 Biolabs, Inc. filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, 20/20 Biolabs, Inc. reported a net loss of $5.06 million on revenues of $1.46 million, compared to a net loss of $2.43 million on revenues of $1.51 million in the prior year period. The company experienced a significant increase in operating expenses, primarily driven by sales, general, and administrative costs, and underwent a major capital restructuring involving the conversion of multiple preferred stock series into common stock.
20/20 Biolabs reported its Q3 2026 financial results, highlighted by a 4.1% increase in OneTest revenue to $1.36 million for the first nine months of the year and a gross margin expansion to 32.8%. The company ended the quarter with $3.63 million in cash and no debt, while securing a new two-year firefighter cancer screening contract with the state of Vermont expected to contribute to revenue in Q4.
Term
Q3 2026
“OneTest™ revenue grew 4.1% through the first nine months of the year, with gross profit increasing 15.6%. While third quarter revenue was below the prior year, much of this reflected the timing of our state-funded firefighter cancer screening programs. Maryland completed a significant portion of its testing in the second quarter, while the start of Vermont’s program shifted into the fourth quarter. Vermont has now executed its two-year contract, and we expect testing to begin contributing to revenue before year-end.”
Jonathan Cohen, President and Chief Executive Officer
“We ended the third quarter with $3.63 million in cash and no outstanding borrowings, compared to $1.03 million in cash at year-end 2025. Our net loss narrowed to $1.38 million from $1.51 million in the second quarter, while operating expenses declined 4.0% sequentially.”
20/20 Biolabs, Inc. reported the results of its adjourned annual meeting of stockholders held on September 16, 2026. Stockholders approved a charter amendment to increase the number of authorized shares of common stock from 50 million to 500 million shares.